HER2-positive (+) breast cancer is a heterogeneous disease [1], accounting for 10–20% of all breast tumors, with approximately half cases expressing also estrogen receptor (ER) and progesterone receptor (PgR) at immunohistochemistry (IHC) [2]. This evidence concerns the gene PGR and breast neoplasm.